Gilead Sciences (GILD) Announces Kite’s Yescarta Becomes First CAR T Therapy Approved by FDA for Treatment of … – StreetInsider.com
|
Gilead Sciences (GILD) Announces Kite’s Yescarta Becomes First CAR T Therapy Approved by FDA for Treatment of …
StreetInsider.com Kite, a Gilead Company, (Nasdaq: GILD) today announced that the U.S. Food and Drug Administration (FDA) has granted regular approval to Yescarta™ (axicabtagene ciloleucel), the first chimeric antigen receptor T cell (CAR T) therapy for the treatment … |
Business Insider |
FDA approves CAR–T cell therapy to treat adults with certain types of large B-cell lymphoma
FDA.gov The U.S. Food and Drug Administration today approved Yescarta (axicabtagene ciloleucel), a cell-based gene therapy, to treat adult patients with certain types of large B-cell lymphoma who have not responded to or who have relapsed after at least two … A cancer treatment that’s part of ‘a big new field of medicine’ just got approvedBusiness Insider FDA follows through with a groundbreaking OK for Yescarta, Gilead’s new CAR–T breakthroughEndpoints News FDA approves a game-changing treatment for blood cancerSTAT (blog) |